211 related articles for article (PubMed ID: 38386415)
1. Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis.
Prakasam G; Mishra A; Christie A; Miyata J; Carrillo D; Tcheuyap VT; Ye H; Do QN; Wang Y; Reig Torras O; Butti R; Zhong H; Gagan J; Jones KB; Carroll TJ; Modrusan Z; Durinck S; Requena-Komuro MC; Williams NS; Pedrosa I; Wang T; Rakheja D; Kapur P; Brugarolas J
J Clin Invest; 2024 Feb; 134(7):. PubMed ID: 38386415
[TBL] [Abstract][Full Text] [Related]
2. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
[TBL] [Abstract][Full Text] [Related]
4. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
5. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.
Kobos R; Nagai M; Tsuda M; Merl MY; Saito T; Laé M; Mo Q; Olshen A; Lianoglou S; Leslie C; Ostrovnaya I; Antczak C; Djaballah H; Ladanyi M
J Pathol; 2013 Apr; 229(5):743-754. PubMed ID: 23288701
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.
Kauffman EC; Ricketts CJ; Rais-Bahrami S; Yang Y; Merino MJ; Bottaro DP; Srinivasan R; Linehan WM
Nat Rev Urol; 2014 Aug; 11(8):465-75. PubMed ID: 25048860
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
[TBL] [Abstract][Full Text] [Related]
8. Dual role of G-quadruplex in translocation renal cell carcinoma: Exploring plausible Cancer therapeutic innovation.
Neha ; Das P; Verma SP
Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129719. PubMed ID: 32882363
[TBL] [Abstract][Full Text] [Related]
9. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
11. RBM10-TFE3 fusions: A FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases.
Di Mauro I; Dadone-Montaudie B; Sibony M; Ambrosetti D; Molinie V; Decaussin-Petrucci M; Bland V; Arbaud C; Cenciu B; Arbib F; Just PA; Derman J; Rioux-Leclercq N; Pedeutour F;
Genes Chromosomes Cancer; 2021 Nov; 60(11):772-784. PubMed ID: 34358382
[TBL] [Abstract][Full Text] [Related]
12. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract][Full Text] [Related]
13. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
[TBL] [Abstract][Full Text] [Related]
14. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.
Wang B; Yin X; Gan W; Pan F; Li S; Xiang Z; Han X; Li D
Autophagy; 2021 Sep; 17(9):2475-2493. PubMed ID: 33019842
[TBL] [Abstract][Full Text] [Related]
15. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
[TBL] [Abstract][Full Text] [Related]
16. Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.
Cao C; Lan X; Shang B; Jiang W; Guo L; Zheng S; Bi X; Zhou A; Sun Z; Shou J
Clin Transl Oncol; 2022 Jul; 24(7):1333-1346. PubMed ID: 35118587
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
[TBL] [Abstract][Full Text] [Related]
18. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
[TBL] [Abstract][Full Text] [Related]
19. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern.
Just PA; Letourneur F; Pouliquen C; Dome F; Audebourg A; Biquet P; Vidaud M; Terris B; Sibony M; Pasmant E
Genes Chromosomes Cancer; 2016 Jun; 55(6):541-8. PubMed ID: 26998913
[TBL] [Abstract][Full Text] [Related]
20. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
